Funder
Abbott Vascular
Amgen Cardiovascular
AstraZeneca
Bayer AG
Boehringer Ingelheim
Boston Scientific
The Bristol Myers Squibb and Pfizer Alliance
The Alliance Daiichi Sankyo Europe GmbH
Eli Lilly and Company
Edwards
Gedeon Richter
Menarini Int. Op.
MSD-Merck & Co.
Novartis Pharma
ResMed
Sanofi
SERVIER
Sanofi-Aventis and Eucomed
Reference21 articles.
1. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS;Kirchhof;Europace,2016
2. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study;Chugh;Circulation,2014
3. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis;Odutayo;BMJ,2016
4. National trends in atrial fibrillation hospitalization, readmission, and mortality for medicare beneficiaries, 1999-2013;Freeman;Circulation,2017
5. Registries in atrial fibrillation: from trials to real-life clinical practice;Mazurek;Am J Med,2017
Cited by
53 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献